• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Fsd Pharma Inc Cl B (NQ: HUGE )

    0.0899 UNCHANGED
    Last Price Updated: 4:00 PM EDT, Aug 14, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Fsd Pharma Inc Cl B

    < Previous 1 2
    ...
    4 5 6 7 8 9 10 11 Next >
    PsychedelicNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Reports Filing of Complaint, Update on Spin-Out Transaction
    Via Investor Brand Network
    FSD Pharma Announces Receipt of Court Action and Update on Spin-Out and Distribution
    From FSD Pharma Inc.
    Via Business Wire
    PsychedelicNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Secures $2.81M in Cost Awards from Dr. Raza Bokhari
    Via Investor Brand Network
    FSD Pharma Awarded $2.81 Million in Cost Awards From Dr. Raza Bokhari
    From FSD Pharma Inc.
    Via Business Wire
    Promising Multiple Sclerosis Drug Candidate Advances: First Clinical Trial Dosing Completed
    FSD Pharma Inc. (NASDAQ: HUGE), a biopharma company developing innovative assets and biotech solutions for the treatment of neurodegenerative, inflammatory and metabolic disorders, announced the first... 
    Via Benzinga
    PsychedelicNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Announces Completion of Phase 1 Dosing in MS Clinical Trial
    Via Investor Brand Network
    FSD Pharma Completes Dosing of First Cohort in Phase I Clinical Trial of Lucid-MS, a New Drug Candidate for the Treatment of Multiple Sclerosis: Safety Review Committee Recommends Commencing Dosing of Second Cohort
    From FSD Pharma Inc.
    Via Business Wire
    Sidoti's Micro-Cap Virtual May Conference
    Via ACCESSWIRE
    Psyched: Psychedelics Reimbursement, Amanita Muscaria Boom, $53M Material Breach Lawsuit & More
    EXCLUSIVE: AMA Moves Toward Psychedelic Therapy Reimbursement, Filing A Gap In Regulations 
    Via Benzinga
    BioMedNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) to Present at Sidoti Virtual Investor Conference
    Via Investor Brand Network
    FSD Pharma to Present at Sidoti Virtual Investor Conference May 10-11
    From FSD Pharma Inc.
    Via Business Wire
    Lawsuit: GBB Drink Lab Seeks $53M From FSD Pharma For Nondisclosure Contract Breach & Trade Secret Misappropriation
    GBB Drink Lab, which makes the world’s first formulated drink that aids in rapid blood alcohol detoxification - a handy tool, has filed a lawsuit against the psychedelics biotech company FSD Pharma... 
    Via Benzinga
    GBB Drink Lab Files $53M Lawsuit Against FSD Pharma for Nondisclosure Contract Breach and Trade Secret Misappropriation
    GBB Drink Lab Files $53M Lawsuit Against FSD Pharma for Nondisclosure Contract Breach and Trade Secret Misappropriation 
    Via News Direct
    Topics Lawsuit
    Exposures Financial Legal
    Psyched: LSD For Major Depression, Canada's Psilocybin Macrodose Trial, Treatments For Multiple Sclerosis And More
    LSD Trial Study Shows Potential For Major Depression Psychedelics biopharma company Mind Medicine Inc. (NASDAQ: MNMD) recently shared positive topline data from an advanced clinical trial of LSD as a... 
    Via Benzinga
    Dynamic Duo of Celsius Holdings Fame join FSD Pharma calling Medical Product under Development “Unique and Disruptive”
    Via AB Newswire
    Topics Bankruptcy
    Exposures Financial Legal
    North America Could Possibly Emerge as the Market Leader for Billion Dollar Detox Drinks Industry
    EQNX::TICKER_START (NASDAQ:CELH),(NASDAQ:OMER),(NYSE:MRK),(NASDAQ:RXDX) EQNX::TICKER_END 
    Via FinancialNewsMedia
    GBB Drink Lab Sends a Cease-and-Desist Demand
    FSD Pharma Breached NDA with GBB After GBB Terminates Acquisition Discussions 
    Via News Direct
    Psyched: Clinical-Grade MDMA, LSD For Depression, Partnerships For Delivering Psychedelic Therapies & More
    Revolutionizing Psychedelics: 2 Industry Leaders Team Up On Clinical-Grade MDMA Capsules 
    Via Benzinga
    Novel Compound Begins Clinical Testing For Potential Treatment Of Multiple Sclerosis
    FSD Pharma Inc. (NASDAQ: HUGE) has dosed the first subjects in its first clinical trial assessing the New Chemical Entity (NCE) Lucid-21-302, or Lucid-MS, targetting multiple sclerosis. 
    Via Benzinga
    PsychedelicNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Completes Critical Step in Advancing Lucid-MS Pipeline
    Via Investor Brand Network
    FSD Pharma Achieves Milestone in Completion of Dosing of Sentinel Subjects in First-in-Human Clinical Trial of Lucid-MS (Lucid-21-302) for Multiple Sclerosis
    From FSD Pharma Inc.
    Via Business Wire
    EXCLUSIVE: Investing In The Unique Growth Market Of Psychedelics
    The global psychedelics market of drugs such as psilocybin, ketamine and LSD is booming and there are plenty of ways to get involved in the space. 
    Via Benzinga
    PsychedelicNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Provides Update on Spin-Out Plan, Announces Shareholder Meeting
    Via Investor Brand Network
    FSD Pharma To Spin Out New Publicly Trading Subsidiary As Distribution To Shareholders
    Psychedelics biotech company FSD Pharma Inc. 
    Via Benzinga
    FSD Pharma Announces Plan to Spin-Out Subsidiary as Distribution to Shareholders; Shareholder Meeting Scheduled for June 29, 2023
    From FSD Pharma Inc.
    Via Business Wire
    FSD Pharma Announces Filing of Year-End 2022 Results
    From FSD Pharma Inc.
    Via Business Wire
    BioMedNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Announces Strategic Board Appointment of Gerry David
    Via Investor Brand Network
    FSD Pharma Adds Former Celsius Holdings CEO Gerry David to Board of Advisors
    From FSD Pharma Inc.
    Via Business Wire
    Psyched: Australia As Psychedelics Hub, Advanced Scans Of Brain On DMT, New PAC For Congressional Influence, 9 States Advancing Bills & More
    Australia: Enveric, FSD Pharma, Psyence & Others Advance Businesses 
    Via Benzinga
    FSD Pharma's Australian Entity To Proceed With Phase I Trial For Major Depressive Disorder
    Biotech company FSD Pharma Inc. (NASDAQ: HUGE)’s Australian business FSD Pharma Australia Pty Ltd. has been approved by the Alfred Ethics Committee to begin a Phase 1 clinical trial of next-gen drug... 
    Via Benzinga
    < Previous 1 2
    ...
    4 5 6 7 8 9 10 11 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.